BioSpace News Archive

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to six new employees.

Revance Therapeutics, Inc. announced a proposed underwritten public offering of its common stock.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

Evidence-Based Guidelines to Drive Improved Care for Patients with ITP

Habhegger Succeeds Don Major Who Will Remain a Consultant for Precision Optics

Sage Therapeutics, Inc. announced that on Monday, December 2, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 4,200 shares of its common stock, and 700 performance restricted stock units to two new employees under Sage’s 2016 Inducement Equity Plan.

Willow Biosciences Inc. announces that it has received final approval from the Toronto Stock Exchange to list its common shares on the TSX.

Creates Potential for Significantly Expanded Test Menu

Johnson & Johnson Consumer Inc. reaffirmed that its Johnson’s Baby Powder is safe and free of asbestos after a comprehensive investigation into the United States Food and Drug Administration’s earlier reported finding of sub-trace levels of asbestos in samples from a single bottle of Johnson’s Baby Powder.

Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit